What does DarioHealth do?
DarioHealth Corp. is a Nasdaq Capital Market healthcare-technology company that combines connected devices, software, coaching, behavioral science, and increasingly provider-backed clinical care. Its platform supports diabetes, prediabetes, hypertension, weight management and GLP-1 support, musculoskeletal conditions, and behavioral-health needs. The aim is one personalized experience across related conditions for employers, plans, providers, and individuals.
Which health problems sit inside the platform?
The company’s official solutions overview emphasizes a consumer-style experience, continuous engagement, and condition-specific clinical outcomes. The strategic idea is a multi-condition platform sold into benefit budgets using a shared data and engagement layer.
How does DarioHealth make money?
Dario has two economically different revenue engines. The first is business-to-business-to-consumer, or B2B2C: employers, health plans, benefit administrators, and channel partners contract for access to programs that eligible members use. The second is direct consumer revenue from hardware, supplies, à-la-carte products, and membership plans. The 2025 Form 10-K describes service revenue as recognized over the contract’s service period and hardware revenue when control transfers, generally at shipment.
Which revenue source matters most?
| Model | Pricing logic | Economic attraction | Main constraint |
|---|---|---|---|
| Per engaged member per month | $74 for bundled cardiometabolic and MSK offerings in the July 2026 presentation | Revenue rises when members activate and remain engaged | Utilization and retention must remain high |
| Per eligible employee per month | Used for behavioral health and some mid-market multi-condition programs | Broad covered population can produce recurring access fees | Low unit pricing requires scale |
| Milestone or outcomes pricing | Five milestones over 12 months; total payments indicated at $500 to $1,000+ per member | Aligns payment with engagement, device use, or clinical outcomes | Revenue timing depends on performance and measurement |
| Consumer products and memberships | Hardware, supplies, subscriptions, and à-la-carte programs | Creates direct user data and faster product feedback | Hardware carries lower margin than enterprise services |
What did DarioHealth’s latest quarter show?
The quarter ended March 31, 2026 showed a mixed operating picture: revenue declined year over year but increased sequentially for a second consecutive quarter, while cost reductions materially narrowed operating loss. The official Q1 2026 earnings release attributed the sequential increase to channel-partner onboarding and stronger direct-to-consumer MSK product sales.
How did the quarterly mix change?
| Q1 metric | 2026 | 2025 | Interpretation |
|---|---|---|---|
| B2B2C revenue | $2.7M | $4.7M | Lower enterprise revenue reflects the transition from a legacy client and timing of new implementations. |
| Consumer revenue | $2.9M | $2.0M | Consumer MSK sales helped offset enterprise pressure. |
| Operating expenses | $10.5M | $13.3M | R&D fell to $2.4M, sales and marketing to $4.9M, and G&A to $3.2M. |
| Gross profit | $3.2M | $3.9M | Lower revenue and higher hardware mix reduced gross profit dollars. |
The latest Form 10-Q also shows that the revenue base is still small relative to operating expenses. Operating margin was approximately negative 131% in Q1 2026, so improved efficiency does not yet equal operating self-sufficiency.
Which turning points explain DarioHealth’s strategy today?
Dario’s current model is the product of a long shift from a connected glucose device toward a broad chronic-care platform. The useful history is not a list of corporate events; it is a sequence of capability additions that expanded the addressable buyer, condition set, and revenue model.
-
2013–2014The Dario glucose-management solution received European certification and entered initial commercial markets, creating the connected-device and direct-user foundation.
-
2016U.S. commercialization expanded the consumer base and produced the long-duration behavioral and biometric data later used in enterprise programs.
-
2020Management broadened beyond diabetes and prioritized business customers, changing the model from device sales toward recurring digital-health contracts.
-
2021The acquisitions of Upright and PsyInnovations added musculoskeletal and behavioral-health capabilities, making a multi-condition proposition possible.
-
2022Physimax technology and strategic collaboration work extended remote assessment, clinical evidence, and partner reach.
-
2024Dario acquired Twill for total accounting consideration of $34.5M, including $10.0M cash, expanding health-plan relationships and the behavioral-health platform.
-
2025–2026Post-merger integration reduced operating expenses, while Dario shifted sales toward larger multi-condition contracts and channel partners.
-
June–July 2026Provider-backed care, DarioIQ, health-plan expansions, and a fifth Fortune 50 employer moved the story from digital engagement toward clinical intervention and land-and-expand monetization.
What gives DarioHealth a competitive advantage?
Dario does not have a conventional moat based on scale or current profitability. Its defensibility rests on reinforcing assets: more than a decade of direct consumer engagement, connected-device data, a multi-condition product architecture, enterprise channels, clinical evidence, and a growing AI layer. The company’s July 2026 investor presentation reported 13B+ proprietary data points, 90% client retention, 100+ published studies, and approximately 70% of new wins involving multiple conditions.
Is the data advantage commercially useful?
Where is the moat still unproven?
The moat therefore has two layers. The product layer is increasingly differentiated; the financial layer remains fragile. Better-funded rivals can imitate features, bundle services, or price aggressively. Dario must prove that its data and breadth produce higher retention, outcomes, and contract expansion faster than competitors can copy the offering.
Who are DarioHealth’s main competitors?
Competition varies by condition and channel rather than by one identical business model. Hinge Health is a major MSK competitor; Omada Health, Teladoc’s Livongo assets, Vida Health, and Virta Health compete in cardiometabolic and chronic-care programs; behavioral-health vendors and large healthcare platforms also compete for benefit budgets. Dario’s own filing warns that several rivals have greater brand recognition, capital, customer relationships, and regulatory experience.
| Competitive arena | Representative rivals | Dario’s claimed differentiation | Pressure on Dario |
|---|---|---|---|
| Cardiometabolic | Omada, Teladoc/Livongo, Vida, Virta | Connected devices, consumer engagement history, and integrated comorbidity management | Long sales cycles, strong incumbents, and outcomes-based pricing |
| Musculoskeletal | Hinge Health and other digital MSK platforms | Ability to combine MSK with metabolic and behavioral programs | Category specialists can invest more heavily in one condition |
| Behavioral health | Digital coaching, navigation, and therapy platforms | Twill assets and integration with physical-health conditions | Crowded employer-benefits market and pricing competition |
| Platform and care delivery | Large health-tech, payer, and provider platforms | Consumer-centric engagement plus provider-backed execution without building a nationwide physician network | Partners may become competitors or control customer access |
How should a strategy student frame industry forces?
Buyer power is high because employers and plans can consolidate vendors or delay implementations, while rivals promise lower cost and better outcomes. Barriers include clinical evidence, privacy and security, device regulation, integrations, and enterprise distribution, but software features alone are copyable. Substitution risk includes in-house payer programs, provider care-management teams, and bundled offerings from larger platforms. Dario’s best defense is to make the multi-condition bundle measurably cheaper and more effective than managing separate vendors.
How financially strong is DarioHealth?
Dario’s 2025 results show substantial cost progress but not financial self-sufficiency. Full-year revenue declined to $22.4M from $27.0M, largely because a legacy Twill client changed scope and did not renew. Gross margin improved to 56.6% from 49.1%, while operating expenses fell to $49.3M from $71.0M. The FY2025 results release reported operating loss of $36.7M and net loss of $41.7M.
What does the balance sheet imply?
| Balance-sheet item | March 31, 2026 | Interpretation |
|---|---|---|
| Cash and cash equivalents | $15.0M | Primary liquidity source before short-term deposits. |
| Short-term deposits | $5.0M | Raises readily available cash and deposits to approximately $20.0M. |
| Long-term loan | $30.9M | Debt exceeds cash and deposits by roughly $10.9M before restricted cash. |
| Current assets / liabilities | $28.7M / $9.4M | Current ratio was about 3.1x, but operating cash burn remains the more important liquidity test. |
| Goodwill | $57.4M | Goodwill represented about 55.6% of total assets, creating impairment sensitivity if acquired businesses underperform. |
That simple runway calculation is not a forecast, but it explains why financing risk remains central. Dario had a $20M at-the-market equity facility, with only $54,000 of gross sales through May 13, 2026. Continued losses could require equity issuance, debt restructuring, or better operating results. Dilution and cost of capital therefore matter as much as the product opportunity.
Who owns DarioHealth stock, and how is it governed?
Dario has one-share-one-vote common stock rather than a founder-controlled dual-class structure. Beneficial ownership disclosed in the 2025 annual report was based on 7.3M common shares outstanding at March 11, 2026. Executives and directors as a group held 250,048 shares, or 3.4%, while CEO Erez Raphael held 99,326 shares, or 1.5%. This means management has economic exposure but does not control shareholder votes.
| Holder or group | Beneficial shares | Reported stake | Governance implication |
|---|---|---|---|
| Executive officers and directors | 250,048 | 3.4% | Meaningful incentives, but no voting control. |
| Erez Raphael, CEO | 99,326 | 1.5% | Long-tenured CEO exposure to common equity. |
| Nantahala Capital Management | 729,311 | 9.9% | Large financial-holder influence; warrants are subject to ownership limits. |
| Tasso Partners | 729,311 | 9.9% | Reported beneficial ownership also includes pre-funded warrants with a 9.99% cap. |
| Craig Kallman 2015 Living Trust | 729,311 | 9.9% | Another concentrated holder near the contractual ownership ceiling. |
What governance issue deserves monitoring now?
Erez Raphael has served as CEO since 2013. Chen Franco-Yehuda became CFO in May 2025. In a July 10, 2026 Form 8-K, Dario said President and Chief Commercial Officer Steven Nelson’s medical leave had been extended indefinitely with duties reassigned to senior management. Because commercial execution is the bottleneck, researchers should monitor implementation and pipeline conversion.
What growth opportunities could change DarioHealth’s scale?
The largest opportunity is not simply signing more logos; it is increasing contract value within a channel-led distribution network. At March 31, 2026, management reported a $127M commercial pipeline across 241 opportunities, $12.9M of contracted and late-stage ARR opportunities, and 95 new contracts signed during 2025 and Q1 2026. Those are pipeline and management-estimate figures rather than recognized revenue, so conversion timing is the key test.
Can Dario expand inside existing accounts?
Two July 2026 announcements illustrate the model. A large national health plan expanded from mental health into hypertension, potentially tripling Dario’s revenue opportunity with that customer. A new Fortune 50 employer contract covers more than 100,000 eligible employees and is expected to begin contributing revenue by year-end 2026. The Fortune 50 contract release described it as Dario’s fifth Fortune 50 client.
What could DarioIQ and provider-backed care add?
The DarioIQ announcement and the Beluga collaboration expand the potential economics, but both remain execution stories. Higher engagement must translate into recognized revenue, gross profit, and lower cash burn.
What risks could weaken DarioHealth’s outlook?
The central risk is a timing mismatch: Dario is investing in a platform and enterprise contracts whose revenue may ramp slowly, while cash leaves the business every quarter. The 2025 client reset demonstrates how one large contract can overwhelm growth elsewhere. The Q1 2026 filing also warns that resources could be consumed more rapidly than expected, requiring additional funding sooner.
| Risk | Current factual anchor | Financial line affected | What to monitor |
|---|---|---|---|
| Liquidity and dilution | $20.0M cash and deposits versus $6.0M Q1 operating cash use | Shares, debt, interest, and cash balance | ATM issuance, debt terms, quarterly burn |
| Implementation delays | Pipeline and signed contracts are larger than current recognized revenue | Revenue growth and deferred revenue | Launch dates, covered lives, revenue conversion |
| Customer concentration | A single legacy Twill client drove much of the FY2025 revenue decline | B2B2C revenue and gross profit | Renewals, scope changes, top-customer dependence |
| Competition and pricing | Larger rivals can bundle or discount offerings | Win rate, price, sales cost, gross margin | Retention, multi-condition share, contract size |
| Regulatory, privacy, and cybersecurity | Connected devices and sensitive longitudinal health data require compliance and controls | Operating expense, liability, reputation | Security events, FDA compliance, privacy changes |
| Acquisition value | $57.4M goodwill was 55.6% of assets at March 31, 2026 | Impairment expense and equity | Twill revenue, synergies, cash-flow forecasts |
Which risk is most important?
Near-term liquidity determines how long Dario has to prove pipeline conversion. Medium-term success requires retention, engagement, expansion, and faster implementation to produce recurring gross profit. A company can have strong outcomes and still destroy equity value if it must repeatedly finance losses on unfavorable terms.
Which KPIs matter most for valuation?
A DCF model for Dario should not begin with a mature margin assumption. It should begin with a bridge from signed business to recognized revenue, then from revenue mix to gross profit, and finally from operating leverage to cash burn. Because management is targeting cash-flow breakeven around mid-2027, the trajectory matters more than any single quarter.
How should a DCF treat the company?
Use three stages: forecast enterprise launches and consumer revenue separately; apply different margins to services and hardware; and assume operating leverage only after scale appears. Terminal value is sensitive because current free cash flow is negative and value depends heavily on distant assumptions. The discount rate should reflect small-company risk, financing dependence, customer concentration, and execution uncertainty.
What is the key takeaway from DarioHealth analysis?
DarioHealth is a small, loss-making healthcare-technology company whose platform is broader than its revenue base. Its strategic case rests on integrated care, longitudinal data, channel distribution, outcomes, and multi-condition expansion. Recent enterprise wins, DarioIQ, provider-backed care, and two consecutive quarters of sequential revenue growth strengthen that narrative.
The financial case is less mature. FY2025 revenue declined, Q1 2026 enterprise revenue remained below the prior year, operating cash burn was $6.0M, and debt exceeded cash and deposits. Gross margin and operating expenses have improved, but substantial operating leverage is still required. Goodwill concentration and potential equity dilution increase the cost of execution errors.
What should researchers monitor next?
- Revenue contribution from the $12.9M contracted and late-stage ARR opportunity set.
- Launch timing for the Fortune 50 employer and expanded health-plan programs.
- B2B2C revenue growth versus consumer hardware growth and the resulting gross-margin mix.
- Whether operating cash use falls materially below the Q1 2026 level of $6.0M.
- Retention, engagement, and realized revenue uplift from DarioIQ.
- Progress toward provider-backed revenue without a disproportionate rise in clinical costs.
- ATM issuance, debt amendments, warrants, and fully diluted share count.
- Commercial execution during the President and Chief Commercial Officer’s leave.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.